Phathom Pharmaceuticals, Inc. (PHAT)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
PHAT Annual Report Details VOQUEZNA Launch and Financial Strategy
# 🧾 What This Document Is This is Phathom Pharmaceuticals' **Annual Report to Shareholders (ARS)**. Think of it as the company's official "year-in-review" newsletter sent directly to its owners (the shareholders). It's more detailed and narrative than the standard financial-only SEC filings, combi
SEC filings
All filings →Insider trades
All insider trades →Phathom Pharmaceuticals, Inc. has no reported insider trades in the last 90 days.